Health News Roundup: Moderna shares slide on concerns over drop in RSV vaccine efficacy; Canada bungled COVID app for travelers, official inquiry finds and more
Novo Holdings would invest about $5 billion a year in the next five years, and that could go up to $7 billion a year by 2030, Kutay said. Weight-loss drugs tied to benefit after hip replacement New diabetes and weight-loss drugs may benefit patients undergoing hip replacement, without adding to complication risks, according to preliminary data released on Monday at a large meeting of orthopedic surgeons.
Following is a summary of current health news briefs.
Novo Nordisk's controlling shareholder plans to invest about $35 billion by 2030
Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk, plans to invest about $35 billion by 2030, CEO Kasim Kutay told Reuters in an interview on Monday. Novo Holdings would invest about $5 billion a year in the next five years, and that could go up to $7 billion a year by 2030, Kutay said.
Weight-loss drugs tied to benefit after hip replacement
New diabetes and weight-loss drugs may benefit patients undergoing hip replacement, without adding to complication risks, according to preliminary data released on Monday at a large meeting of orthopedic surgeons. In one study reviewing use of Ozempic - the brand name for Novo Nordisk’s semaglutide prescribed for hard-to-control diabetes – the drug was associated with 44% lower odds of developing an infection of the newly implanted joint, after other risk factors were taken into account, researchers said. Semaglutide is sold under the name Wegovy for weight-loss.
Takeda's treatment becomes first oral therapy for esophageal condition in US
Takeda Pharmaceutical's therapy for an allergic inflammation of the esophagus has received approval from the U.S. FDA, the Japanese drugmaker said on Monday, capping a years-long regulatory process. The U.S. health regulator's approval makes the therapy the first oral treatment for the condition, which currently only has Sanofi and Regeneron's injection Dupixent.
Children traumatised by Nepal quake need aid to rebuild lives - UNICEF
About 68,000 children and their families who survived Nepal’s deadliest quake in eight years need further humanitarian aid to rebuild their lives, UNICEF said on Sunday, 100 days after the tremors that devastated parts of west Nepal. A 6.4 magnitude earthquake struck two districts of Jajarkot and Rukum West in the remote western region of the Himalayan country on Nov. 3, killing at least 154 people, more than half of them children.
Gilead to buy CymaBay for $4.3 billion in bets on liver disease treatment
Gilead Sciences has agreed to buy CymaBay Therapeutics for $4.3 billion, gaining access to an experimental liver disease treatment with blockbuster potential as the U.S. drugmaker looks beyond its older HIV drugs for growth. Shares of the Newark, California-based drug developer jumped 24.6% to a record high of $32.01 in morning trading on Monday, compared to the offer price of $32.50 per share. Gilead's shares rose 1.1% to $74.49.
Canada bungled COVID app for travelers, official inquiry finds
The Canadian government bungled a COVID-era app for travelers at every stage, failed to keep records and poorly utilized funds, the country's top watchdog said in a highly critical report on Monday. The Canada Border Services Agency (CBSA), working with the health and public services ministries, launched the ArriveCAN application in April 2020 to collect health information from travelers and assist with quarantine measures.
Proteins may predict who will get dementia 10 years later, study finds
A study of frozen blood samples has turned up a trove of proteins that may predict several forms of dementia more than 10 years before the disease is diagnosed, researchers from the U.K. and China reported on Monday. The study, published in the journal Nature Aging, is part of ongoing research from multiple teams to identify patients at risk for dementia using a simple blood test, an advance many scientists believe will accelerate the development of new treatments.
Moderna shares slide on concerns over drop in RSV vaccine efficacy (Feb 9)
Data posted on Thursday ahead of an RSV conference next week showed an efficacy of about 63% after 8.6 months in preventing RSV-related respiratory disease, down from 84% at 3.3 months.
(With inputs from agencies.)